Two businesses moving in different directions

The interim results of EKF Diagnostics (LSE:EKF), published on 15 September 2026, showed a Business split between a growing Life Sciences arm and a Point-of-Care division that slipped in the first half. Group Revenue for the six months to 30 June 2026 was £25.0m, down 1% from £25.2m. With no material announcements since September, those results remain the main evidence for how the year is progressing.

The board said its expectations for the 2026 financial year were unchanged, and that it expected revenue and adjusted EBITDA growth in line with market expectations. The company cited consensus forecasts of £54.6m of revenue and £13.6m of adjusted EBITDA. On our arithmetic, meeting that revenue figure implies second-half revenue of about £29.6m, materially above the first-half revenue figure.

Where growth came from

Life Sciences revenue rose 8% to £10.0m. Within it, beta-hydroxybutyrate products grew 4% to £7.4m, fermentation rose 14% to £1.6m and contract Manufacturing increased 25% to £1.0m. The company plans to trade its fermentation and contract manufacturing activities under the name Nexus Bioworks, centred on its Facility in South Bend, Indiana. It fully exited its former Elkhart, Indiana site on 30 June 2026, a year earlier than planned, after a one-off settlement of US$0.4m, or £0.3m.

Point-of-Care revenue fell 3% to £15.0m. Hematology, the largest product line, slipped to £7.8m from £8.0m, diabetes was flat at £5.5m and lactate eased to £0.6m. The company said most of the delayed Point-of-Care revenue was expected in the second half, supported by existing orders, and that its DiaSpect product would shift its focus to US blood banks.

The company's five-year plan rests on three pillars: growing contract manufacturing and fermentation, expanding beta-hydroxybutyrate sales and accelerating Point-of-Care hematology. The first half therefore offered mixed evidence, with two pillars growing and the third declining slightly.

Margins, cash and capital

Gross Margin improved to 53.0% from 50.2%, and adjusted EBITDA rose 2.4% to £5.9m. Profit before tax was £3.4m, compared with £3.6m, while profit attributable to shareholders rose 19.3% to £2.3m. Free Cash Flow fell to £1.1m from £3.7m, and net cash from operations declined to £3.3m from £4.9m. Cash stood at £16.0m at 30 June, with no borrowings, although £2.4m of that was held in Russia and subject to restrictions.

During the half, EKF (LSE:EKF) repurchased and cancelled 3.554 million shares for £0.9m. The shares were about 23.5p at the close of the 2 November session. The Americas generated £12.9m of revenue, just over half of the group total, which leaves results exposed to US Demand and to movements in the dollar.

What could go wrong

The clearest dependency is timing. If the delayed Point-of-Care orders slip again, the second half would have to rely more heavily on Life Sciences, which is smaller. Chief executive Gavin Jones said the company was "confident that Point-of-Care Hematology will deliver growth in H2 2026", but that is a management expectation rather than a result.

Contract manufacturing and fermentation growth depends on winning and retaining customers for the South Bend facility, and the restricted Russian cash is not freely available to the group. The medium-term ambition of more than £80m of revenue and more than £20m of adjusted EBITDA by 2029 is a target, not a forecast, and requires growth well above the first-half rate.

Next steps

EKF has not announced a date for its next trading update. Investors should watch for confirmation of whether the delayed Point-of-Care revenue arrived in the second half, how Nexus Bioworks is building its customer base and whether share repurchases continue. By the interim stage, EKF said it had bought back 23.5 million shares at an average of 25.2p, returning £5.9m to shareholders.